title: Appraisal of efficacy and safety of intralesional injection of high concentration of bleomycin A5 for treatment of huge macrocystic lymphatic malformations in cervical region.
abstract: The objective of this study was to investigate the therapeutic effects and safety of intralesional injection of high concentration of bleomycin A5 for huge (more than 5 cm in diameter) macrocystic lymphatic malformations (LMs) in the cervical region. Thirty-two patients with huge macrocystic LMs were treated with percutaneous injection of bleomycin A5 in our department between 2006 and 2011. Among them, 13 patients had unilateral submandibular lesions, and 19 patients had lesions in anterior cervical regions. The age of patients ranged from 10 months to 29 years (mean age, 11.4 y). The concentration of the drug was as high as 2.7 mg/mL (8 mg/3 mL) with an addition of dexamethasone. The mean sessions of injection were 1.6 (1-3 sessions). Repeated injection interval was 4 to 6 weeks. The follow-up period was 6 months to 4 years after the last treatment, and the mean follow-up time was 18 months. The results were evaluated based on clinical examination and Doppler ultrasonography scan. The clinical follow-up showed excellent response in 28 of the 32 patients, whereas 4 of the 32 patients also had a satisfactory response. No serious complications were encountered. Intralesional injection of high concentration of bleomycin A5 was an effective and safe treatment of huge macrocystic LMs in the cervical region and can obtain satisfactory results esthetically and functionally without surgery.
authors.affiliation: From the Departments of *Oral and Maxillofacial Surgery, China Medical University, Shenyang; and †Department of Oral and Maxillofacial Surgery, He Fei Stomatological Hospital, Hefei, PR China.
authors.forename: Da-Peng
authors.initials: DP
authors.lastname: Xu
authors.forename: Qin-Kai
authors.initials: QK
authors.lastname: Zhai
authors.forename: Chen
authors.initials: C
authors.lastname: Cheng
authors.forename: He
authors.initials: H
authors.lastname: Gong
authors.forename: Hong-Wei
authors.initials: HW
authors.lastname: Wang
authors.forename: Xu-Kai
authors.initials: XK
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D044148:Lymphatic Abnormalities / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D009333:Neck / Q000000981:diagnostic imaging; D017060:Patient Satisfaction; D012074:Remission Induction; D012449:Safety; D016896:Treatment Outcome; D018608:Ultrasonography, Doppler / Q000379:methods; D055815:Young Adult
chemical_list: D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; C025703:bleomycetin